Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: Marc Kahn who wrote (235)	7/14/1998 11:19:00 PM
From: Cube	Respond to of 534

Marc, Don't be disappointed. Yesterday's trading left a big gap in the chart at about 1.75. If the price had not drifted down today to close that gap, technical analysis traders would have always been skeptical as to when that gap will be filled. Now we can look forward to a gapless healthy uptrend with no TA guys worrying. Cube

To: Marc Kahn who wrote (235)	7/17/1998 9:27:00 AM
From: geewiz	Respond to of 534

Hi Marc, all, Interesting article in current issue of Forbes about MiniMed and the diabetes market; forbes.com type in ALFRED MANN in search to get full article; For Private use only: Mann came up with a lower-cost version of an early insulin pump for diabetes sufferers in 1995 while on his first vacation in ten years. While Paris slept, he was drawing diagrams in a frenzy at a table in his hotel room. "His idea of a good vacation is sitting poolside in Hawaii with a stack of papers and a red pen," says his daughter, Carla, who's in business development at Advanced Bionics, one of Mann's private companies (she's no slouch herself, with six patents pending at age 29). "Sometimes he complains of his long hours, but usually with a smirk. He loves it. He's a kid in a candy store." Many of those hours are spent at publicly traded MiniMed, Inc. of Sylmar, Calif., where he is 35% owner and chief executive officer. MiniMed controls 80% of the U.S. market (and 20% of Europe's) for external insulin pumps-beeper-size devices that infuse the missing stuff into diabetes patients' bloodstreams. At MiniMed he's working on an artificial pancreas of sorts-an insulin pump that will be implanted under the abdomen to send insulin into the bloodstream as needed for people afflicted with Type 1 diabetes, whose bodies produce no insulin. To date, those patients, as well as many of the larger group suffering milder diabetic problems with age, have used the external pump. As it now stands, diabetics must prick their fingertips to test their blood at breakfast, lunch, dinner and bedtime. Between the four checks a day, patients' blood sugar levels vary widely and sometimes fall life-threateningly low. The new MiniMed device, which feels like a hockey puck, is intended to include a continuous glucose sensor for automatic dosages. The innovation awaits Food & Drug Administration approval. A lot hangs on the decision. Studies by the National Institutes of Health and the American Diabetes Association show that continuous treatments help diabetics live better and longer. About 840,000 Americans suffer from Type 1 diabetes, and the number is expected to grow by about 31% in the next five years. With $136 billion spent annually treating diabetics in the U.S., Mann believes his product will save tens of billions of dollars. Those expectations explain why MiniMed trades near $50, giving the company a market capitalization of $650 million and a price/earnings ratio of 54. copywrite Forbes Magazine After reading it I wonder if diabetics want implants, and if so are the HMO's be willing to pay? Great news on Merk!!!! Hope more are comming soon. best, art